LATE BREAKING CLINICAL TRIALS

LATE BREAKING CLINICAL TRAILS IS NOW CLOSED

SUBMISSION OF ABSTRACTS GUIDELINES

1. Breaking Clinical Trial abstracts are targeted towards randomized clinical trial data,
   large population-based trial evidence, or novel translational evidence that is likely to
   be highly cited and impactful in clinical practice.
2. Retrospective investigations or metanalyses will not be considered. Similarly, ad interim
   results of ongoing randomized trials will not be selected.
3. Exempt from publication in EJCTS
4. Previously presented data can be submitted for consideration, but this will be reviewed by the Program Committee and assessed for suitability to present.
5. The presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission.
6. The presenting author must be listed as the first author.
7. All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
8. Please submit symbols as words.
9. All abstracts accepted for a presentation will be published on the Meeting website prior to the Meeting.

10. **Please note the presenting author will receive all correspondence about the abstract so we advise that the submitting author details that are entered are the same details as those of the presenting author.**
11. **Abstracts may not be edited/updated after final submission. You are welcome to bring an updated poster onsite with you.**
12. **Your abstract is not successfully submitted until you receive a confirmation e-mail after clicking the final submit button. If you do not receive a confirmation e-mail, please contact us.**
13. Company or product names are not allowed in the title

Abstract Format:

Context:

Objective:

Design, Setting, Participants:

Interventions:

Main Outcome Measure:

Results:

Conclusions:

Trial Registration:

Funding:

Maximum 300 words and Two Table